期刊文献+

二肽基肽酶4抑制剂对心血管系统的保护作用研究进展 被引量:2

原文传递
导出
摘要 目的:为二肽基肽酶4(DPP-4)抑制剂的临床合理应用提供新的思路与方法。方法:以"DPP-4抑制剂""糖尿病""心血管系统""危险因素"等组合作为关键词,查阅1999-2013年中国期刊全文数据库、万方数据库、维普数据库、Pub Med中有关DPP-4抑制剂对心血管系统影响作用和机制的文献,并进行汇总分析。结果:共查阅文献410篇,其中有效27篇。DPP-4抑制剂在有效控制血糖的同时,可减少2型糖尿病患者心血管事件和全因死亡。其具有减少患者心肌梗死面积和改善心功能的作用,对心脏起到直接的保护作用,同时也具有保护血管内皮功能的作用。其对患者体质量、血压、血脂等心血管危险因素可有效控制和改善,从而降低心血管疾病的发生率。但目前的研究数据有限,DPP-4抑制剂对心血管系统的作用机制及作用是否存在选择性和特异性,与其他药物是否存在相互作用,是否存在长期影响及潜在的安全隐患等尚未完全明确。结论:DPP-4抑制剂在保护心血管系统方面显示出重要的临床应用价值,可为2型糖尿病的治疗提供新的思路与方法,同时也需进行更为深入和广泛的研究。
作者 段蓉 李正翔
出处 《中国药房》 CAS CSCD 2014年第45期4305-4308,共4页 China Pharmacy
  • 相关文献

参考文献27

  • 1Andr6 J. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors : from risk factors to clinical outcomes[J]. Post- graduate Med, 2013,125(3):7.
  • 2Hemmingsen B, Lund SS, Gluud C, et al. Intensive gly- caemic control for patients with type 2 diabetes: systemat- ic review with meta-analysis and trial sequential analysis of randomised clinical trials[J]. BMJ, 2011, 343 (24) : d6 898.
  • 3Monami M, Ahr6n B, Dicembrini I, et al. Dipeptidyl pepti- dase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials[J]. Diabetes Obesity Metab, 2013,15(2) :112.
  • 4Frederich R, Alexander JH, Fiedorek FT, et al. A systemat- ic assessment of cardiovascular outcomes in the saxa- gliptin drug development program for type 2 diabetes[J]. Postgraduate Med, 2010,122(3) : 16.
  • 5杨晶晶,宋滇平.DPP-4抑制剂治疗与心血管疾病:利与弊[J].实用糖尿病杂志,2012,8(6):8-10. 被引量:2
  • 6Huisamen B, Genis A, Marais E, et al. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats[J]. Cardiovasc Drugs Ther, 2011,25 ( 1 ) : 13.
  • 7Ye Y, Keyes KT, Zhang C, et al. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA[J]. Am J Physiol Heart Circ Physiol, 2010,298(5) :HI 454.
  • 8Ban K, Noyan-AshrafMH, Hoefer J, etal. Cardioprotec- rive and vasodilatory actions ofglucagon-like peptide 1 re- ceptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways[J]. Circu- lation, 2008,117 ( 18 ) : 2 340.
  • 9Sauv6 M, Ban K, Ma MM, et al. Genetic deletion or ph- armacological inhibition of dipeptidyl peptidase-4 im- proves cardiovascular outcomes after myocardial infarc- tion in mice[J]. Diabetes, 2010,59(4) : 1 063.
  • 10Read PA, Khan FZ, Heck PM, et al. DPP-4 inhibition by sitagliptin improves the myocardial response to dobuta- mine stress and mitigates stunning in a pilot study of pa- tients with coronary artery disease[J]. Cire Cardiovase Im- aging,2010,3(2) : 195.

二级参考文献13

  • 1Matikainen N, Manttari S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride - rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006 ;49 (9) : 2049 - 2057.
  • 2Tremblay AJ, Lamarche B, Deacon CF, et al. Effect of sitagliptin therapy on. postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab 2011 ;3 (4) :366 - 373.
  • 3Brandt I, Lambeir AM, Ketelslegers JM, et al. Dipeptidyl - peptidase Ⅳ converts intact B - type natriuretic peptide into its des - SerPro form. Clin Chem 2006 ;52:82 - 87.
  • 4Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase - 4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double - blind, non - inferiority trial. Diabetes Obes Metab 2007 ;9 (2) : 194 - 205.
  • 5Mason RP, Jacob RF, Kubant R, et al. Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. J Atheroscler Thromb 2011 ; 18 ( 9 ) : 774 - 783.
  • 6Bauvois B, De Meester I, Dumont J, et al. Constitutive expression of CD26/dipeptidylpeptidase Ⅳ on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia. Br J Cancer 1999;79: 1042-1048.
  • 7Takasawa W, Ohnuma K, Hatano R, et al. Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Biochem Biophys Res Commun 2010;401(1) :7 -12.
  • 8Huisamen B, Genis A, Marais E, et al. Pre - treatment with a DPP - 4 inhibitor is infarct sparing in hearts from obese, pre - diabetic rats. Cardiovasc Drugs Ther 2011 ;25 ( 1 ) : 13 - 20.
  • 9Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010; 122 (3) : 16 - 27.
  • 10Ban K, Noyan - Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon - like peptide 1 receptor are mediated through both glucagon - like peptide 1 receptor- dependent and - independent pathways. Circulation 2008; 117 ( 18 ) :2340 - 2350.

共引文献1

同被引文献13

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部